Dan Brennan
Stock Analyst at TD Cowen
(4.01)
# 541
Out of 4,944 analysts
109
Total ratings
51.14%
Success rate
11.53%
Average return
Main Sectors:
Stocks Rated by Dan Brennan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADPT Adaptive Biotechnologies | Maintains: Buy | $13 → $15 | $12.74 | +17.74% | 1 | Aug 6, 2025 | |
| CAI Caris Life Sciences | Initiates: Buy | $32 | $34.88 | -8.26% | 1 | Jul 14, 2025 | |
| GH Guardant Health | Maintains: Buy | $56 → $60 | $57.40 | +4.53% | 2 | May 1, 2025 | |
| WGS GeneDx Holdings | Maintains: Buy | $135 → $110 | $117.66 | -6.51% | 4 | May 1, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Neutral | $8 → $2.5 | $2.78 | -10.07% | 4 | Mar 21, 2025 | |
| TEM Tempus AI | Reinstates: Buy | $74 | $69.00 | +7.25% | 2 | Feb 5, 2025 | |
| EXAS Exact Sciences | Maintains: Buy | $82 → $86 | $42.70 | +101.41% | 6 | Nov 26, 2024 | |
| NTRA Natera | Maintains: Buy | $155 → $175 | $157.44 | +11.15% | 4 | Nov 13, 2024 | |
| CRL Charles River Laboratories International | Maintains: Buy | $240 → $250 | $152.16 | +64.30% | 5 | Nov 7, 2024 | |
| BRKR Bruker | Maintains: Hold | $72 → $70 | $33.31 | +110.15% | 1 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $166 → $177 | $99.66 | +77.60% | 12 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $88.97 | +61.85% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $363 → $410 | $287.52 | +42.60% | 3 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $310 → $315 | $206.94 | +52.22% | 5 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $153 → $160 | $118.44 | +35.09% | 12 | Aug 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $28 → $30 | $6.06 | +395.05% | 1 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $31 | $12.74 | +143.33% | 3 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $648 → $658 | $483.10 | +36.20% | 12 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $51 | $43.50 | +17.24% | 2 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2.8 | $0.43 | +548.15% | 1 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $6.21 | +222.06% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $57 → $32 | $13.53 | +136.51% | 4 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $545 → $546 | $196.56 | +177.78% | 4 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $2.82 | +148.23% | 1 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $13 → $15 | $1.32 | +1,040.68% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $207 → $232 | $175.53 | +32.17% | 6 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $770 → $880 | $1,302.77 | -32.45% | 3 | Oct 7, 2020 |
Adaptive Biotechnologies
Aug 6, 2025
Maintains: Buy
Price Target: $13 → $15
Current: $12.74
Upside: +17.74%
Caris Life Sciences
Jul 14, 2025
Initiates: Buy
Price Target: $32
Current: $34.88
Upside: -8.26%
Guardant Health
May 1, 2025
Maintains: Buy
Price Target: $56 → $60
Current: $57.40
Upside: +4.53%
GeneDx Holdings
May 1, 2025
Maintains: Buy
Price Target: $135 → $110
Current: $117.66
Upside: -6.51%
Maravai LifeSciences Holdings
Mar 21, 2025
Maintains: Neutral
Price Target: $8 → $2.5
Current: $2.78
Upside: -10.07%
Tempus AI
Feb 5, 2025
Reinstates: Buy
Price Target: $74
Current: $69.00
Upside: +7.25%
Exact Sciences
Nov 26, 2024
Maintains: Buy
Price Target: $82 → $86
Current: $42.70
Upside: +101.41%
Natera
Nov 13, 2024
Maintains: Buy
Price Target: $155 → $175
Current: $157.44
Upside: +11.15%
Charles River Laboratories International
Nov 7, 2024
Maintains: Buy
Price Target: $240 → $250
Current: $152.16
Upside: +64.30%
Bruker
Nov 6, 2024
Maintains: Hold
Price Target: $72 → $70
Current: $33.31
Upside: +110.15%
Nov 5, 2024
Maintains: Buy
Price Target: $166 → $177
Current: $99.66
Upside: +77.60%
Nov 5, 2024
Maintains: Buy
Price Target: $141 → $144
Current: $88.97
Upside: +61.85%
Nov 4, 2024
Maintains: Hold
Price Target: $363 → $410
Current: $287.52
Upside: +42.60%
Oct 23, 2024
Maintains: Buy
Price Target: $310 → $315
Current: $206.94
Upside: +52.22%
Aug 22, 2024
Maintains: Buy
Price Target: $153 → $160
Current: $118.44
Upside: +35.09%
Aug 7, 2024
Maintains: Hold
Price Target: $28 → $30
Current: $6.06
Upside: +395.05%
Jul 29, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $12.74
Upside: +143.33%
Jul 25, 2024
Maintains: Buy
Price Target: $648 → $658
Current: $483.10
Upside: +36.20%
Jul 23, 2024
Maintains: Buy
Price Target: $48 → $51
Current: $43.50
Upside: +17.24%
May 13, 2024
Initiates: Buy
Price Target: $2.8
Current: $0.43
Upside: +548.15%
May 1, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $6.21
Upside: +222.06%
May 1, 2024
Downgrades: Hold
Price Target: $57 → $32
Current: $13.53
Upside: +136.51%
Dec 8, 2023
Maintains: Outperform
Price Target: $545 → $546
Current: $196.56
Upside: +177.78%
May 31, 2023
Initiates: Outperform
Price Target: $7
Current: $2.82
Upside: +148.23%
Mar 31, 2023
Upgrades: Outperform
Price Target: $13 → $15
Current: $1.32
Upside: +1,040.68%
Mar 1, 2021
Upgrades: Buy
Price Target: $207 → $232
Current: $175.53
Upside: +32.17%
Oct 7, 2020
Downgrades: Sell
Price Target: $770 → $880
Current: $1,302.77
Upside: -32.45%